Paras, G., Gulati, R., Blinka, S. M., Raychaudhuri, R., Khan, H. M., Gagnon, A., Woo, B., Yu, E. Y., Grivas, P., Cheng, H. H., Yezefski, T., Nadal, R., Hsieh, A. C., Montgomery, R. B., Nelson, P., Schweizer, M. T. (2026). SPECTRA study: A phase II trial of supraphysiological androgen to enhance treatment activity with DNA-damaging agents in men with metastatic castration resistant prostate cancer (mCPRC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps279